ENTX Entera Bio: Rasio rega marang prakiraan pendapatan
How can Entera Bio Ltd. (ENTX) attract leading biochemists to develop oral proteins? The forward revenue multiple illustrates the business valuation trend, where 1512.30 shows the current value of the metric. Stability is ensured by independence from GDP cycles and FDA approval, while the environmental footprint is minimized through the safe disposal of laboratory reagents.
Rincian metrik komprehensif lan analitis enterabio.com (ENTX)
- rega saiki lan proyeksi nilai saham:
- data kapitalisasi saham perusahaan:
- indikator nilai buku ekuitas:
- indikator total utang lan likuiditas perusahaan:
Utang marang Ekuitas Entera Bio Ltd.|ENTX - Koefisien utang jangka dawa marang modal|Utang jangka cendhak marang modal Entera Bio|ENTX - Gunggung utang perusahaan|Utang marang nilai buku ENTX|ENTX - Silihan lan utang jangka dawa perusahaan|Utang jangka cendhak perusahaan Entera Bio|Rasio cepet enterabio.com
- indikator pendapatan resik lan kelipatan nilai:
ENTX - Asil keuangan resik|Bathi sing dikarepake Entera Bio Ltd.|ENTX - Kapitalisasi marang bathi|Prakiraan rega marang bathi Entera Bio|ENTX - Koefisien bali modal nimbang wutah|Nilai perusahaan marang bathi sadurunge bunga, pajeg, lan panyusutan ENTX|ENTX - Bathi sadurunge mbayar bunga, pajak, lan amortisasi|Bathi resik saben saham sajrone 12 wulan pungkasan Entera Bio|ENTX - Bathi saben saham sajrone patang kuartal pungkasan|Wutah bathi EPS kuartalan enterabio.com|ENTX - Wutah bathi saben saham ing taun iki|Prakiraan wutah bathi saben saham kanggo taun ngarep Entera Bio Ltd.
- rincian pendapatan lan dodolan emiten:
Analisis fundamental perusahaan:Entera Bio Corp (ENTX)
For Entera Bio Ltd. (ENTX), which monetizes oral platforms through high-margin licensing, this indicator reflects market expectations for future revenue streams. The expected P/S valuation is calculated as the ratio of current market capitalization to projected sales volume, where an upward trend in the line signals a rising premium for technological superiority, while a decline indicates a devaluation of the business.
Pesaing wigati
Multiplikator Forward P/S HLN (Haleon)|Kenvue Inc (KVUE) - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|VRNA - Rasio rega marang prakiraan pendapatan|MENS (Jyong Bio) - Kapitalisasi marang prakiraan pendapatan|LGND (Ligand Pharmaceuticals) - Multiplikator forward rega marang pendapatan|AMRX: Rasio rega marang pendapatan sing dikarepake|PRGO (Perrigo) - Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Alvotech S.A. ALVO|Rasio rega marang prakiraan pendapatan Liquidia Technologies (LQDA)|GLPG (Galapagos Corp) - Rega forward marang dodolan|Multiplikator Forward P/S ANIP (ANI Pharmaceuticals)|Multiplikator Forward P/S mannkindcorp.com MNKD|AMPH: Multiplikator forward rega marang pendapatan|Rega forward marang dodolan PCRX (Pacira Pharmaceuticals)|SPRY: Multiplikator Forward P/S|TBPH (Theravance Corp) - Rasio rega marang prakiraan pendapatan|AQST (Aquestive Therapeutics) - Multiplikator Forward P/S|scPharma (SCPH) - Rasio kapitalisasi marang dodolan sing dikarepake|Rasio rega marang prakiraan pendapatan Tectonic Therapeutic, Inc. (TECX)|TNXP - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|China SXT Pharmaceuticals, Inc. - Multiplikator forward rega marang pendapatan|Rega forward marang dodolan EPRX|BHST - Rasio rega marang prakiraan pendapatan|EXOZ: Rasio rega marang prakiraan pendapatan|ORMP (oramed.com) - Multiplikator forward rega marang pendapatan|HYFT: Rasio rega marang pendapatan sing dikarepake|ABVC (ABVC BioPharma Inc) - Multiplikator Forward P/S|Kapitalisasi marang prakiraan pendapatan CPIX (Cumberland Corp)|Multiplikator forward rega marang pendapatan QNTM (Quantum BioPharma Ltd)|Rasio kapitalisasi marang dodolan sing dikarepake fibrogen.com|Multiplikator Forward P/S TELO (Telomir Pharmaceuticals, Inc.)|Rani Therapeutics Holdings (RANI) - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|SNYR - Rasio rega marang prakiraan pendapatan|RLYB (Rallybio Corporation) - Kapitalisasi marang prakiraan pendapatan|LEXX (lexariabioscience.com) - Multiplikator forward rega marang pendapatan|PULM: Rasio rega marang pendapatan sing dikarepake|Multiplikator forward rega marang pendapatan PTHL|Kapitalisasi marang prakiraan pendapatan APM (Aptorum)|Rasio rega marang prakiraan pendapatan Lyra Therapeutics, Inc (LYRA)|IBO: Rega mangsa ngarep marang pendapatan|Multiplikator Forward P/S TNFA (TNF Pharmaceuticals, Inc.)|Rega forward marang dodolan YCBD|PainReform - Multiplikator Forward P/S|CYTO - Multiplikator Forward P/S|Lipella (LIPO) - Rasio rega marang prakiraan pendapatan|OptiNose Corp - Rega forward marang dodolan|Rasio rega marang prakiraan pendapatan Pieris Pharmaceuticals|Multiplikator forward rega marang pendapatan procapsgroup.com (PROC)|Multiplikator Forward P/S PTPI|Multiplikator Forward P/S Qilian International Holding Group (QLI)|ACELYRIN, Inc. - Multiplikator forward rega marang pendapatan|Rega forward marang dodolan TFFP
